• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Upexi Adjusted SOL per Share Increases 129% Since Treasury Launch

    9/11/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email

    Unrealized gain now stands at $142 million1

    TAMPA, Fla., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today released its periodic update.

    "The last several weeks were extremely strong for Upexi, highlighted by a substantial increase in the price of SOL," stated Upexi CEO Allan Marshall. "As a result, our Solana treasury now stands at $447 million, including an unrealized gain of $142 million. Moreover, we continued to expand our visibility, welcoming Arthur Hayes to our newly-established Advisory Committee, and met with many high-quality investors at three traditional finance conferences."

    Brian Rudick, Chief Strategy Officer, added, "Upexi has uniquely demonstrated our ability to create value for shareholders – we have closed three successful capital issuances, with all three deals materially in the money; we have generated a $142 million or 46% unrealized gain in our treasury to benefit shareholders; and we have increased our adjusted SOL per share by 129% since launching the treasury strategy, demonstrating the multiple value accrual mechanisms and efficacy of our treasury management operations."

    Below are highlights from the last several weeks.

    Treasury Update as of September 10, 2025

    • Treasury: Upexi held 2,018,419 SOL, up 1% from the 2,000,518 SOL on August 4, 2025.
    • Net Asset Value: Using the September 10, 2025 price of $221.59 per SOL2, the 2,018,419 SOL are valued at $447 million.
    • Unrealized Gain: The cost of Upexi's SOL totals $306 million, or $151.44 per SOL. The unrealized gain, which includes both price appreciation and the discount on locked SOL, stands at $142 million.
    • SOL per Share: Upexi is introducing a new adjusted SOL per share metric, described more below, where as of September 10, adjusted SOL per share was 0.0197 or $4.37, up 56% and 126%, respectively, from the launch of the Solana treasury strategy.
    • Staking: Substantially all the Company's SOL are being staked, earning an ~8% yield. The current daily yield is approximately $105,000 per day in revenue.
    • Locked SOL: Approximately 53% of the portfolio is locked SOL purchased at a mid-teens discount to the spot price and providing for built-in gains for shareholders.
    • Valuation: Using the closing price of Upexi stock on September 10, 2025, Upexi traded at a Basic mNAV of 0.7x and a Fully-Loaded mNAV of 1.2x.



    Business Initiatives

    • Advisory Committee: Upexi established an Advisory Committee composed of highly prominent individuals from digital assets and traditional finance and welcomed Arthur Hayes as its first Advisor.
    • Special Meeting: Upexi held a Special Meeting of Stockholders where stockholders approved increasing the number of shares the Company may issue, at its sole discretion, under its equity line.
    • Investor Conferences: Upexi participated in the Canaccord Genuity 45th Annual Growth Conference, the 5th Annual Needham Virtual Crypto Conference, and the H.C. Wainwright 27th Annual Global Investment Conference.



    Upexi Events / Multimedia Recap

    • Canaccord Genuity 45th Annual Growth Conference fireside chat
    • H.C. Wainwright 27th Annual Global Investment Conference presentation
    • Milk Road Podcast
    • Thinking Crypto Podcast
    • Unchained Bits + Bips Podcast



    Adjusted SOL per Share

    Upexi is introducing a new adjusted SOL per share metric, which management believes can supplement investor analysis, as it adjusts for items that may heavily skew basic SOL per share numbers like investment timing and leverage and is therefore the best metric by which to gauge the efficacy of the Company's treasury management operations.

    Management believes that adjusted SOL per share denominated in SOL measures value creation from the company's three value accrual mechanisms in accretive capital issuance, staking revenue, and discounted locked SOL purchases, but excludes the impact of the change in the price of SOL to the greatest extent possible. Here, Upexi has 0.0197 in adjusted SOL per share, up from 0.0127 upon the close of Upexi's initial $100 million equity private placement in April, for an increase of 56%.

    In dollar terms, adjusted SOL per share captures the three aforementioned value accrual mechanisms as well as the change in the price of SOL. Upexi's adjusted SOL per share now stands at $4.37, up from $1.93 following the close of Upexi's initial $100 million equity private placement in April, for an increase of 126%.

    Adjusted SOL per Share 
            
        September 10, 2025  
     April 24, 2025 Share Count   
     Share Count  Shares issued & outstanding58,893,261  
     Shares issued & outstanding, March 31, 20251,430,429 Shares underlying $150m convertible note35,292,206  
     April 2025 PIPE common shares35,970,383 Share count (adjusted)94,185,467  
     April 2025 PIPE pre-funded warrants7,889,266     
     Share count (adjusted)45,290,078 SOL Held   
        Total SOL held2,018,419  
     SOL Held  Net cash-35,500,000  
     Net cash from April 2025 PIPE87,500,000 SOL price, September 10, 2025$221.59  
     SOL price, April 24, 2025$152.33 Net cash (in SOL)-160,206  
     SOL held (adjusted)574,411 SOL held (adjusted)1,858,213  
            
     Adjusted SOL / share (in SOL)0.0127 Adjusted SOL / share (in SOL)0.0197  
     Adjusted SOL / share (in USD)$1.93 Adjusted SOL / share (in USD)$4.37  
            

    Sources: Yahoo Finance, CoinMarketCap, Company filings. Note: Assumes net proceeds from the April equity private placement are deployed into spot SOL upon raise close.

    About Upexi, Inc.

    Upexi is a brand owner specializing in the development, manufacturing, and distribution of consumer products. The Company has entered the cryptocurrency industry and cash management of assets through a cryptocurrency portfolio. For more information on Upexi's treasury strategy and future developments, visit www.upexi.com.

    Follow Upexi on X - https://x.com/upexitreasury

    Follow CEO, Allan Marshall, on X - https://x.com/upexiallan

    Follow CSO, Brian Rudick, on X - https://x.com/thetinyant

    Forward Looking Statements

    This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. For example, the Company is using forward looking statements when it discusses the anticipated use of proceeds. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration, and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

    Company Contact

    Brian Rudick, Chief Strategy Officer

    Email:[email protected]

    Phone: (216) 347-0473

    Media Contact

    Gasthalter & Co.

    [email protected]

    Investor Relations Contact

    KCSA Strategic Communications

    Valter Pinto, Managing Director

    (212) 896-1254

    [email protected]

    ______________________________

    1 Includes both SOL price appreciation and the discount on locked SOL. 

    2 Price of SOL as of 4:00pm ET quoted on coinmarketcap.com.



    Primary Logo

    Get the next $UPXI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Adjusted SOL per Share Increases 129% Since Treasury Launch

    Unrealized gain now stands at $142 million1 TAMPA, Fla., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today released its periodic update. "The last several weeks were extremely strong for Upexi, highlighted by a substantial increase in the price of SOL," stated Upexi CEO Allan Marshall. "As a result, our Solana treasury now stands at $447 million, including an unrealized gain of $142 million. Moreover, we continued to expand our visibility, welcoming Arthur Hayes to our newly-established Advisory Committee, and met with m

    9/11/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Participate in Upcoming September Conferences

    TAMPA, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced that management will participate in the following September 2025 investor conferences. Conference details, including links to webcasts, can be found below. 5th Annual Needham Virtual Crypto ConferenceDates: September 4, 2025Location: VirtualAttendees: Brian Rudick, Chief Strategy OfficerType: Investor Meetings H.C. Wainwright 27th Annual Global Investment ConferenceDates: September 8-10, 2025Location: Lotte New York Palace

    9/3/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. Announces Strategic Investment in Alpha Exchange

    TAMPA, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its initial strategic investment in Cybersyn Holdings, LLC ("Cybersyn"), owner of Alpha Exchange, a next-generation cryptocurrency trading platform built to serve both new and experienced investors that is expected to launch in the fourth quarter of 2025. The Alpha Exchange platform combines AI-driven trading insights, real-time analytics, and intuitive tools with institutional-grade security and strict regulatory complian

    8/28/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    9/8/25 5:20:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form S-1/A filed by Upexi Inc.

    S-1/A - UPEXI, INC. (0001775194) (Filer)

    9/5/25 5:23:15 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form S-1/A filed by Upexi Inc.

    S-1/A - UPEXI, INC. (0001775194) (Filer)

    9/5/25 5:20:51 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $799,998 worth of shares (161,943 units at $4.94) and was granted 1,200,000 shares, increasing direct ownership by 154% to 2,246,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:08 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    CSO Rudick Brian Benjamin was granted 400,000 shares, increasing direct ownership by 91% to 838,597 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:09:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Leadership Updates

    Live Leadership Updates

    View All

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Financials

    Live finance-specific insights

    View All

    Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million

    TAMPA, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 83,000 SOL for $16.7 million, or $201.34 per SOL. The purchase brings the Company's holdings to 1.9 million SOL worth over $381 million using the $200.60 spot price of Solana as of 5:00 pm ET yesterday. Allan Marshall, Chief Executive Officer of Upexi, remarked, "The U.S. continues to make progress around digital asset legislation, which has the potential to usher in mass adoption of blockchain technology.

    7/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

    Upexi purchased an additional 100,000 SOL, and anticipates it may generate up to approximately $26 million in annual staking revenue based on current SOL holdingsCompany releases adjusted metrics for enhanced transparency and analysis TAMPA, Fla., July 21, 2025 (GLOBE NEWSWIRE) --  Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 100,000 SOL, bringing its treasury holdings to 1,818,809 SOL worth $331 million. The recent purchase follows the successful closing of a roughly $200 million equity and c

    7/21/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Regains Compliance with NASDAQ

    Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

    12/23/24 9:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care